Company
Umoja Biopharma, Inc.
Pioneering In Vivo CAR T Cell Therapies
Also known as Umoja Biopharma
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Seattle, WA, United States
- Legal name
- Umoja BioPharma, Inc.
- umoja-biopharma.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Umoja Biopharma, Inc. is a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives.
Funding snapshot
- Total raised
- $210MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $210M2021-06-09
Funding rounds
- Round, 2021
- $210M2021-06-09, SEC form D sold, 29 investors
Loading relationship preview